[ The text begins. ]
2010
Best M&A Deal
| Astellas Pharma’s US$4.078 billion acquisition of OSI Pharmaceuticals | Asiamoney (Announced in February, 2011) |
BEST INTERNATIONAL BOND
| Mitsubishi Corp. US$500 million 2.75% bonds due 2015 | Asiamoney (Announced in February, 2011) |
BEST BOND
| SMBC €750 million, 10-year bullet lower tier 2 offering | The Asset (Announced in February, 2011) |
Best M&A Deal (In-Out)
| Astellas’ takeover of OSI Pharmaceuticals | Euromoney Japan (Announced in January, 2011) |
Best International Bond Deal
| Japan Finance Corporation (Japan Bank for International Cooperation) |
Euromoney Japan (Announced in January, 2011) |
2010 Greenwich Associates Survey (published in November, 2010)
Japanese Sales, Research & Trading (European Equity Investors)
| #2 Overall Penetration in Japanese Equity Research | |
| #2 Overall Research & Analyst Service Quality |
Nikkei Veritas (Announced in March, 2010)
1st Ranked Sectors
| Sector | Analyst |
|---|---|
| Health Care & Pharmaceuticals | Hidemaru Yamaguchi |
| Bank | Hironari Nozaki |
| Category | |
|---|---|
| Overall | Hironari Nozaki |
| Corporate Analysts | Hironari Nozaki |
| Strategy | Tsutomu Fujita |
